LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Articles
Eleven Therapeutics Ltd.
Headquarters:
Tel Aviv, Israel
Website:
https://eleventx.com/
Year Founded:
2020
Status:
Private
BioCentury
|
Jan 12, 2024
Management Tracks
Ajer leaving BioMarin as head of commercial
Plus: Paloma Giangrande named CTO at Eleven and updates from LenioBio and Depixus
Read More
BioCentury
|
Oct 13, 2023
Politics, Policy & Law
Biotech in a time of war
Israel’s biotechs are resilient, determined to continue
Read More
BioCentury
|
Aug 3, 2022
Finance
Aug. 2 Quick Takes: Yescarta label expansion buoys Gilead’s 2Q22 sales
Plus Megaround for Sironax, and updates from Eleven, Roche, Axcella, Phathom, and more
Read More
BioCentury
|
Feb 8, 2022
Finance
Feb. 7 Quick Takes: WuXi Biologics shares fall after landing on Commerce list
Plus mega-rounds for Endeavor, Dewpoint and updates from Koneksa, ObsEva and more
Read More
BioCentury
|
Oct 20, 2021
Finance
NFX seeks to seed more platforms at the tech-bio intersection
With its third and largest fund, early investor in Twist and Mammoth aims to bulk up its NFX Bio portfolio
Read More
Items per page:
10
1 - 5 of 5